Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226369 · ClinicalTrials.gov registry record · Phase 2
Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery
A Phase 2 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 242
- Enrollment target
NCT00226369: Completed Phase 2 study, sponsored by Boston Children's Hospital.
NCT00226369 is a Phase 2 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 242 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00226369, a Phase 2 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 242 participants
- Enrollment target
Study Summary
We conducted a multicenter, randomized, placebo-controlled trial of Cylexin, an inhibitor of the attachment of white blood cells to the endothelium. Our study population was neonates and infants undergoing hypothermic cardiopulmonary bypass during surgical repair or palliation of congenital heart defects.
Interventions
- DRUG CY-1503
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 1997-12 |
| Est. Completion | 2001-06 |
| Phase | Phase 2 |
What the finished NCT00226369 record still lists
NCT00226369 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% higher).
The record links to 0 conditions, and to 1 intervention - of which CY-1503 is the first listed.
NCT00226369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00226369 about?
NCT00226369 is a clinical study titled "Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery". We conducted a multicenter, randomized, placebo-controlled trial of Cylexin, an inhibitor of the attachment of white blood cells to the endothelium. Our study population was neonates and infants undergoing hypothermic cardiopulmonary bypass during surgical repair or palliation of congenital heart de...
What is the current status of trial NCT00226369?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 242 participants. The study started on 1997-12. Estimated completion is 2001-06.
What interventions are being tested in trial NCT00226369?
The interventions under investigation include: CY-1503 (DRUG).
Who is sponsoring clinical trial NCT00226369?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00226369's enrollment target sits among peer trials
242 237th of 2000 higher than 1,762 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia